Plain-English translation of NCT06274593 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing a newer imaging technology called optical coherence tomography angiography (OCTa) to see how well it can detect changes in the blood vessels around the optic nerve in people with advanced glaucoma. Glaucoma damages nerve cells in the eye over time and is a leading cause of irreversible blindness. Researchers believe that studying these blood vessel changes may help doctors catch glaucoma progression earlier and monitor treatment more effectively.
Current methods for monitoring glaucoma—like visual field tests and nerve thickness measurements—don't always catch disease progression quickly. This study explores whether the new imaging technology can provide better information about what's happening in the eye, potentially leading to earlier detection of glaucoma worsening.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have specialized eye imaging scans performed, likely during clinic visits at Nantes University Hospital. These scans use the new OCTa technology to photograph the blood vessels around your optic nerve and take other standard glaucoma measurements. The imaging is non-invasive and painless—the camera does not touch your eye. The study does not involve taking medications or making lifestyle changes.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France
Sponsor
Nantes University Hospital
Enrollment target
~50 participants
Started
April 2024
Primary completion
April 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jean-Baptiste Ducloyer, M.D
Nantes University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.